NCT05461430已完成不适用
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Travera Inc
- 入组人数
- 72
- 试验地点
- 2
- 主要终点
- BOR
研究概览
简要总结
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is ≥18 years of age
- •Written Informed Consent provided by patient
- •Diagnosis of any kind of carcinoma
- •Malignant fluid (e.g. pleural effusion or ascites) drainage OR tumor tissue resection OR tumor tissue needle biopsy is clinically indicated as part of SOC
- •Proceeding onto therapy for treatment
- •Informed consent obtained for the XCELSIOR longitudinal outcomes registry (NCT03793088)
排除标准
- •Lack of informed consent
- •Unable to obtain sufficient sample
结局指标
主要结局
BOR
时间窗: 12 months
Best overall response
次要结局
- PFS(24 months)
研究者
研究点 (2)
Loading locations...
相似试验
终止
不适用
Prospective Tumor Response EvaluationHepatocellular CancerMetastatic Liver CancerNCT02787954The University of Texas Health Science Center, Houston10
Unknown
不适用
Identification and Evaluation of Circulating Tumor Cells and Tumor Related Rare Cells in ImmunotherapyCTC and Tumor Related Rare CellNCT03434912MiCareo Taiwan Co., Ltd.80
撤回
不适用
Bio-marker Analysis Using Circulating Tumor Cells in Patients With MelanomaMelanomaNCT02828345Abramson Cancer Center at Penn Medicine
已完成
1 期
An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker AssessmentAdvanced CancerNCT03335540Bristol-Myers Squibb20
已完成
2 期
Screening Study for Participants With Malignant TumorsSolid TumorsNCT05419375Hoffmann-La Roche470